BVC COP

Pfizer Inc. (PFE.CL)

Compare

95,280.00

-2,540.00

(-2.60%)

At close: April 16 at 3:52:46 PM EDT

Pfizer (PFE) Laps the Stock Market: Here's Why

Pfizer (PFE) closed the most recent trading day at $22.15, moving +0.48% from the previous trading session.

Zacks 2 hours ago

PFE

^GSPC
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). In June 2024, ACIP postponed a vote on a recommendation for adults aged 50-59 at increased risk for RSV-LRTD until additional data becomes available. The update includes Pfizer Inc.’s (NYSE:PFE) Abrysvo (Respiratory Syncyt

Benzinga 4 hours ago

GSK

PFE

MRNA
Is Pfizer Inc. (PFE) the Best Large-Cap Value Stock to Buy as the Recession Hits?

We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best large-cap value stocks to buy as the recession hits. Goldman Sachs highlighted that equities around the world traded in and […]

Insider Monkey 5 hours ago

PFE
Pfizer (NYSE:PFE) Gets CDC Recommendation to Expand ABRYSVO Vaccine Use for RSV Prevention

Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at increased risk. Despite this positive development, Pfizer's shares saw a 2% decline over the past week. This move is in line with broader market trends, as the market dropped by 3% during the same period. The company's decision to halt development of Danuglipron, an oral weight loss drug, due to safety concerns, may have also added weight to the downward pressure on its...

Simply Wall St. 6 hours ago

PFE
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?

Bristol Myers is looking to turn its business around, banking on the strong uptake of new drugs. However, the 2025 outlook is not bright and we recommend investors to wait and watch for now.

Zacks 6 hours ago

CELG-RT

PFE
Lilly Soars as Study Positions Weight-Loss Pill to Pass Ozempic

(Bloomberg) -- Eli Lilly & Co. shares surged after its experimental pill helped patients shed weight and control blood sugar about as well as Ozempic, an advance that could turbocharge what’s already one of the fastest growing markets in medicine.Most Read from BloombergTrump Signs Executive Orders on Federal Purchasing, Office SpaceDOGE Places Entire Staff of Federal Homelessness Agency on LeaveHow Did This Suburb Figure Out Mass Transit?Why the Best Bike Lanes Always Get BlamedNashville’s $3 B

Bloomberg 7 hours ago

LLY

PFE

AZN
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.

Zacks 9 hours ago

PFE

MRNA

CVAC
GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59

The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high risk of severe RSV disease.

Zacks 10 hours ago

PFE

MRNA
Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback

JNJ beats first-quarter estimates for earnings and sales. PFE ends the development of the weight loss pill danuglipron.

Zacks 10 hours ago

PFE

SNY

ROG.SW
Trump Tariff Plunge: 3 Phenomenal Stocks to Buy at Bargain Prices Right Now

Tariff uncertainty has created an ideal opportunity for long-term investors to pounce.

Motley Fool 16 hours ago

PFE

COMP

SPGI
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease

NEW YORK, April 16, 2025--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). This includes ABRYSVO® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug A

Business Wire yesterday

PFE
Why Pfizer Stock Topped the Market on Tuesday

On Tuesday, investors continued to snap up shares of big pharmaceutical company Pfizer (NYSE: PFE). On Tuesday, Pfizer's stock closed the day 1.5% higher, providing a pleasant contrast to the S&P 500 index's 0.2% dip. Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday that it halted the development of its investigational weight loss drug danuglipron.

Motley Fool 2 days ago

PFE
Pfizer Halts Obesity Pill Development Amid Safety Concerns

PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.

Zacks 2 days ago

PFE

LLY

NVO
BofA keeps Neutral on Pfizer after danuglipron failure as core thesis unchanged

BofA analyst Tim Anderson notes Pfizer (PFE) announced danuglipron, an oral GLP-1 obesity, is being discontinued, following a case of liver injury seen in the phase 1 study. The firm points out that it has argued that this program has received almost too much attention – not because obesity isn’t important, but because this was only phase 1 data. Without danuglipron, Pfizer’s obesity pipeline now consists of a GIP receptor antagonist in phase 2 and a phase 1 oral GLP-1 in T2D with Nxera Pharma.

TipRanks 2 days ago

PFE
Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill

Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts “limited reaction” in Pfizer’s shares following the news, JPMorgan tells investors that the decision is “mostly a positive” for Structure and Viking, both developing drugs in the

TipRanks 2 days ago

NONOF

NVO

LLY
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback

Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.

Zacks 2 days ago

PFE

NVO

VKTX
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight Loss Pill?

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 candidate for weight management. Pfizer's stock price is way down, but the quarterly dividend it pays has risen for 16 consecutive years.

Motley Fool 2 days ago

PFE
Why Viking Therapeutics, Inc. (VKTX) Skyrocketed On Monday?

We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other biotech stocks that dominate Monday’s top gainers. The stock market kicked off the shortened trading week on a positive note, with Wall Street’s major […]

Insider Monkey 2 days ago

VKTX

PFE
Trump Initiates Chips and Drug Probes Ahead of More Tariffs

(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergHow Did This Suburb Figure Out Mass Transit?The Secret Formula for Faster TrainsEven Oslo Has an Air Quality ProblemNYC Tourist Helicopter Crashes in Hudson River, Killing SixLisbon Mayor Wants Companies to Help Fix City’s Housing ShortagePresident Donald Trump’s administration pressed forward with plans to impose tariffs on semiconductor and pharmaceutical imports by initiating trade

Bloomberg 2 days ago

TD

TDBKF

000660.KS
Pfizer hits setback in obesity drug race as GLP-1 trial halts

Pfizer (PFE) is ending a late-stage trial of its once-daily GLP-1 pill, Danuglipron, after a participant experienced a liver injury. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination Overtime to break down the details, as well as preview what to watch as Johnson & Johnson (JNJ) prepares to report earnings. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.

Yahoo Finance Video 3 days ago

PFE

JNJ

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Pfizer Inc. (PFE.CL)

Pfizer (PFE) Laps the Stock Market: Here's Why

US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years

Is Pfizer Inc. (PFE) the Best Large-Cap Value Stock to Buy as the Recession Hits?

Pfizer (NYSE:PFE) Gets CDC Recommendation to Expand ABRYSVO Vaccine Use for RSV Prevention

Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?

Lilly Soars as Study Positions Weight-Loss Pill to Pass Ozempic

Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59

Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback

Trump Tariff Plunge: 3 Phenomenal Stocks to Buy at Bargain Prices Right Now

ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease

Why Pfizer Stock Topped the Market on Tuesday

Pfizer Halts Obesity Pill Development Amid Safety Concerns

BofA keeps Neutral on Pfizer after danuglipron failure as core thesis unchanged

Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill

NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback

Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight Loss Pill?

Why Viking Therapeutics, Inc. (VKTX) Skyrocketed On Monday?

Trump Initiates Chips and Drug Probes Ahead of More Tariffs

Pfizer hits setback in obesity drug race as GLP-1 trial halts